Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rapid Micro Biosystems ( (RPID) ) has issued an update.
On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.
The most recent analyst rating on (RPID) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.
Spark’s Take on RPID Stock
According to Spark, TipRanks’ AI Analyst, RPID is a Neutral.
Rapid Micro Biosystems’ overall score is influenced by strong revenue growth and positive technical indicators. However, profitability issues, negative cash flows, and poor valuation metrics weigh heavily. Improvements in gross margins and strategic collaborations provide some optimism, but persistent high expenses and macroeconomic uncertainties remain significant concerns.
To see Spark’s full report on RPID stock, click here.
More about Rapid Micro Biosystems
Average Trading Volume: 143,282
Technical Sentiment Signal: Buy
Current Market Cap: $153.4M
Learn more about RPID stock on TipRanks’ Stock Analysis page.